NCIt definition : An orally bioavailable, highly selective small molecule inhibitor of the gamma isoform
of phosphoinositide-3 kinase (PI3K-gamma) with potential immunomodulating and antineoplastic
activities. Upon administration, eganelisib prevents the activation of the PI3K-gamma-mediated
signaling pathways, which may lead to a reduction in cellular proliferation in PI3K-gamma-expressing
tumor cells. In addition, this agent is able to modulate anti-tumor immune responses
and inhibit tumor-mediated immunosuppression. Unlike other isoforms of PI3K, the gamma
isoform is overexpressed in certain tumor cell types and immune cells; its expression
increases tumor cell proliferation and survival. By selectively targeting the gamma
isoform, PI3K signaling in normal, non-neoplastic cells is minimally or not affected,
which results in a reduced side effect profile.;
UNII : FOF5155FMZ;
InChIKey : XUMALORDVCFWKV-IBGZPJMESA-N;
CAS number : 1693758-51-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1693758-51-8
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)